Multiple genetic abnormalities of 11p15 in Wilms' tumor

Medical and Pediatric Oncology

Volumn 27, Issue 5, 1996, Pages 484-489

  Feinberg, Andrew P ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SOMATOMEDIN B;

ARTICLE; BECKWITH WIEDEMANN SYNDROME; CHROMOSOME 11P; CHROMOSOME LOSS; GENOME IMPRINTING; HUMAN; NEPHROBLASTOMA; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

BECKWITH-WIEDEMANN SYNDROME; CHILD; CHROMOSOME ABERRATIONS; CHROMOSOME DISORDERS; CHROMOSOME MAPPING; CHROMOSOMES, HUMAN, PAIR 11; GENE DELETION; GENES, TUMOR SUPPRESSOR; GENOMIC IMPRINTING; HUMANS; KIDNEY NEOPLASMS; MUTATION; WILMS TUMOR;

EID: 0029816225     PISSN: 00981532     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-911X(199611)27:5<484::AID-MPO16>3.0.CO;2-A     Document Type: Article

References (61)

1. Knudson AG, Strong LC: Mutation and cancer: A model for Wilms' tumor of the kidney. J Natl Cancer Inst 48:313-324, 1972.
2. Fearon ER, Vogelstein B, Feinberg AP: Somatic deletion and duplication of genes on chromosome 11 in Wilms' tumors. Nature 309:176-178, 1984.
3. Call KM, Glaser T, Ito CY, Buckler AJ, Pelletier J, Haber DA, Rose EA, Krai A, Yeger H, Lewis W, Jones C, Housman D: Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locus. Cell 60:509-520, 1990.
4. Gessler M, Poustka A, Cavenee W, Neve RL, Orkin SH, Bruns GA: Homozygous deletion in Wilms' tumours of a zinc-finger gene identified by chromosome jumping. Nature 343:774-778, 1990.
5. Kriedberg JA, Sariola H, Loring JM, Maeda M, Pelletier J, Housman D, Jaenisch R: WT1 is required for early kidney development Cell 74:679-691, 1994.
6. Rauscher FJ, Morris JF, Tournay OE, Cook DM, Curran T: Binding of the Wilms' tumor locus zinc finger protein to the EGR-1 consensus sequence. Science 250:1259-1262, 1990.
7. Wang AY, Madden SL, Deuel TF, Rauscher FJ III: The Wilms' tumor gene product, WT1, represses transcription of the platelet-derived growth factor A-chain gene. J Biol Chem 267:21999-22002, 1992.
8. Pelletier J, Bruening W, Kashtan CE, Mauer SM, Manivel JC, Striegel JE, Houghton DC, Junien C, Habib R, Fouser L, Housman D: Germline mutations in the Wilms' tumor suppressor gene are associated with abnormal urogenital development in Denys-Drash syndrome. Cell 67:437-447, 1991.
9. Huff V, Miwa H, Haber DA, Call KM, Housman D, Strong DC, Saunders GF: Evidence of WT1 as a Wilms' tumor (WT) gene: intragenic germinal deletion in bilateral WT. Am J Hum Genet 48:997-1003, 1991.
10. Little MH, Prosser J, Condie A, Smith PJ, van Heyningen V, Hastie ND: Zinc finger point mutations within the WT1 gene in Wilms' tumor patients. Proc Natl Acad Sci USA 89:4791-4795, 1992.
11. Hastie ND: Wilms' tumor gene and function. Curr Opin Genet Dev 3:408-413, 1993.
12. Reeve AE, Sih SA, Raizis AM, Feinberg AP: Loss of allelic heterozygosity at a second locus on chromosome 11 in sporadic Wilms' tumor cells. Mol Cell Biol 9:1799-1803, 1989.
13. Koufos A, Hansen MF, Copeland NG, Jenkins NA, Lampkin BC, Cavenee WK: Loss of heterozygosity in three embryonal tumours suggests a common pathogenic mechanism. Nature 316:330-334, 1985.
14. Fearon ER, Feinberg AP, Hamilton SH, Vogelstein B: Loss of genes on the short arm of chromosome 11 in bladder cancer. Nature 318:377-380, 1985.
15. Zheng J, Robinson WR, Ehlen T, Yu MC, Dubeau L: Distinction of low grade from high grade human ovarian carcinomas on the basis of losses of heterozygosity on chromosomes 3, 6, and 11 and HER-2/neu gene amplification. Cancer Res 51:4045-4051, 1991.
16. Ali IU, Lidereau R, Theillet C, Callahan R: Reduction to homozygosity of genes on chromosome 11 in human breast neoplasia. Science 238:185-188, 1987.
17. Weston A, Willey JC, Modali R, Sugimura H, McDowell EM, Resau J, Light B, Haugen A, Mann DL, Trump BF, Harris CC: Differential DNA sequence deletions from chromosomes 3, 11, 13, and 17 in squamous-cell carcinoma, large-cell carcinoma, and adenocarcinoma of the human lung. Proc Natl Acad Sci USA 86:5099-5103, 1991.
18. Bepler G, Garcia-Blanco M: Three tumor-suppressor regions on chromosome lip identified by high-resolution deletion mapping in human non-small-cell lung cancer. Proc Natl Acad Sci USA 91:5513-5517, 1994.
19. Miyagi M, Inazawa J, Takita K, Nakamura Y: Cloning and characterization of an interstital deletion at chromosome 11p15 in a sporadic breast cancer. Hum Mol Genet 1:705-708, 1992.
20. Garvin AJ, Re GG, Tarnowski BI, Hazen-Martin DJ, Sens DA: The G401 cell line, utilized for studies of chromosomal changes in Wilms' tumor, is derived from a rhabdoid tumor of the kidney. Am J Pathol 142:375-380, 1993.
21. Dowdy SF, Fasching CL, Araujo D, Lai K, Livanos E, Weissman BE, Stanbridge EJ: Suppression of tumorigenicity in Wilms' tumor by the p15.5-p14 region of chromosome 11. Science 254:293-295, 1991.
22. Koi M, Johnson LA, Kalikin LM, Little PFR, Nakamura Y, Feinberg AP: Tumor cell growth arrest caused by subchromosomal transferable DNA fragments from human chromosome 11. Science 260:361-364, 1993.
23. Goss SJ, Harris H: Gene transfer by means of cell fusion. J Cell Sci 25:17-37, 1977.
24. Loh WE, Jr, Scrable HJ, Livanos E, Arboleda MJ, Cavenee WK, Oshimura M, Weissman BE: Human chromosome 11 contains two different growth suppressor genes for embryonal rhabdomyosarcoma. Proc Natl Acad Sci USA 89:1755-1759, 1992.
25. Pettenati MJ, Haines JL, Higgins RR, Wappner RS, Palmer CG, Weaver DD: Wiedemann-Beckwith syndrome: Presentation of clinical and cytogenetic data on 22 new cases and review of the literature. Hum Genet 74:143-354, 1986.
26. Engstrom W, Lindham S, Schofield P: Wiedemann-Beckwith syndrome. Eur J Pediatr 147:450-457, 1988.
27. Wiedemann HR: Tumors and hemihypertrophy associated with Wiedemann-Beckwith syndrome. Eur J Pediatr 141:129, 1983.
28. Aleck KA, Hadro TA: Dominant inheritance of Wiedemann-Beckwith Syndrome: Further evidence for transmission of "unstable premutation" through carrier women. Am J Med Genet 33:155-160, 1989.
29. Litz CE, Taylor KA, Qiu JS, Pescovitz OH, de Martinville B: Absence of detectable chromosomal and molecular abnormalities in monozygotic twins discordant for the Wiedemann-Beckwith syndrome. Am J Med Genet 30:821-833, 1988.
30. Brown KW, Gardner A, Williams JC, Mott MG, McDermott A, Maitland NJ: Paternal origin of 11p15 duplications in the Beckwith-Wiedemann syndrome. Cancer Genet Cytogenet 58:66-70, 1992.
31. Mannens M, Hoovers JMN, Redeker E, Verjaal M, Feinberg AP, Little P, Boavida M, Coad N, Steenman M, Bliek J, Niikawa N, Nakamura Y, de Boer EG, Slater RM, John R, Cowell JK, Junien C, Henry I, Tommerup N, Weksberg R, Pueschel SM, Leshot NJ, Westerveld A: Parental Imprinting of Human Chromosome Region 11p15-pter involved in the Beckwith-Wiedemann syndrome and Various Human Neoplasia. Eur J Hum Genet 2:3-23, 1994.
32. Ping AJ, Reeve AE, Law DJ, Young MR, Boehnke M, Feinberg AP: Genetic linkage of Beckwith-Wiedemann syndrome to 11p15. Am J Hum Genet 44:720-723, 1989.
33. Koufos A, Grundy P, Morgan K, Aleck KA, Hadro T, Lampkin BC, Kalbakji A, Cavenee WK: Familial Wiedemann-Beckwith syndrome and a second Wilms' tumor locus both map to 11p15.5. Am J Hum Genet 44:711-719, 1989.
34. Hoovers JMN, Kalikin LM, Johnson LA, Alders M, Redeker B, Law DJ, Bliek H, Steenman M, Benedict M, Wiegant J, Cremer T, Taillon-Miller P, Schlessinger D, Edwards MC, Elledge SJ, Ivens A, Westerveld A, Little P, Mannens M, Feinberg AP: Multiple genetic loci within 11p15 defined by Beckwith-Wiedemann syndrome rearrangement breakpoints and subchromosomal transferable fragments. Proc Natl Acad Sci USA, 92:12456-12460, 1995.
35. Kajii T, Ohama K: Androgenetic origin of hydatidiform mole. Nature 268:633, 1977.
36. Linder D, McCaw B, Kaiser X, Hecht F: Parthenogenetic origin of benign ovarian teratomas. N Engl J Med 292:63-66, 1975.
37. Schroeder WT, Chao LY, Dao DD, Strong LC, Pathak S, Riccardi V, Lewis WH, Saunders GF: Nonrandom loss of maternal chromosome 11 alleles in Wilms' tumors. Am J Hum Genet 40:413-420, 1987.
38. Scrable H, Cavenee W, Ghavimi F, Lovell M, Morgan K, Sapienza C: A model for embryonal rhabdomyosarcoma tumorigenesis that involves genome imprinting. Proc Natl Acad Sci USA 86:7480-7484, 1989.
39. Feinberg AP: Genomic imprinting and gene activation in cancer. Nature Genet 4:110-113, 1993.
40. Henry I, Bonaitijk-Pellie C, Chehensse V, Beldjord C, Schwartz C, Utermann G, Junien C: Uniparental paternal disomy in a genetic cancer-predisposing syndrome. Nature 351:665-667, 1991.
41. Heary I, Peuch A, Riesewijk A, Ahnine L, Mannens M, Beldjord C, Bitoun P, Tournade MF, Landrieu P, Junien C: Somatic mosaicism for partial paternal isodisomy in Wiedemann-Beckwith syndrome: a post-fertilization event. Eur J Hum Genet 1:19-29, 1993.
42. DeChiara TM, Robertson EJ, Efstratiadis A: Parental imprinting of the mouse insulin-like growth factor-II gene. Cell 64:849-859, 1991.
43. Bartolomei M, Zemel S, Tilghman SM: Parental imprinting of the mouse H19 gene. Nature 351:153-155, 1991.
44. El-Badry OM, Minniti C, Kohn EC, Houghton PJ, Daughaday WH, Helman LJ: Insulin-like growth factor II acts as an autocrine growth and motility factor in human rhabdomyosarcoma tumors. Cell Growth Dif 1:325-331, 1990.
45. Minniti CP, Maggi M, Helman LJ: Suramin inhibits the growth of human rhabdomyosarcoma by interrupting the insulin-like growth factor-II autocrine growth loop. Cancer Res 52:1830-1835, 1992.
46. Macaulay VM, Everard MJ, Teale JD, Trott PA, Van Wyk JJ, Smith EE, Millar JI: Autocrine function for insulin-like growth factor I in human small cell lung cancer cell lines and fresh tumor cells. Cancer Res 50:2511-2517, 1990.
47. Brannan CI, Dees Ec, Ingram RS, Tilghman SM: The product of the H19 H19 gene may function as an RNA. Mol Cell Biol 10:28-36, 1990.
48. Brunkow ME, Tilghman SM: Ectopic expression of the H19 gene in mice causes prenatal lethality. Genes Dev 5:1092-1101, 1991.
49. Hao Y, Crenshaw T, Moulton T, Newcomb E, Tycko B: Tumor-suppressor activity of H19 RNA. Nature 365:764-767, 1993.
50. Rainier S, Johnson LA, Dobry CJ, Ping AJ, Grundy PE, Feinberg AP: Relaxation of imprinted genes in human cancer. Nature 362:747-749, 1993.
51. Ogawa O, Eccles MR, Szeto J, McNoe LA, Yun K, Maw MA, Smith PJ, Reeve AE: Relaxation of insulin-like growth factor II sene imprinting implicated in Wilms' tumour. Nature 362:749-751, 1993.
52. Zhan SL, Shapiro DN, Helman LJ: Activation of an imprinted allele of the insulin-like growth factor II gene implicated in rhabdomyosarcoma. J Clin Invest 94:445-448, 1994.
53. Rainier S, Dobry C, Feinberg AP: Loss of imprinting in hepatoblastoma. Cancer Res 55:1836-1838, 1995.
54. Steenman MJ, Rainier S, Dobry CJ, Grundy P, Horon IL, Feinberg AP: Loss of imprinting of IGF2 is linked to reduced expression and abnormal methylation of H19 in Wilms' tumor. Nature Genet 7:433-439, 1994.
55. Weksberg R, Shen DR, Fei YL, Song QL, Squire J: Disruption of insulin-like growth factor-II imprinting in Beckwith-Wiedemann syndrome. Nature Genet 5:143-150, 1993.
56. Matsuoka S, Edwards MC, Bai C, Parker S, Zhang P, Baldini A, Harper JW, Elledge SJ: p57/KIP2, a structurally distinct member of the p21/CIP1 Cdk inhibitor family, is a candidate tumor suppressor gene. Genes Dev 9:650-662, 1995.
57. El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzloer KW, Vogelstein B: WAF1, a potential mediator of p53 tumor suppression. Cell 75:817-825, 1993.
58. Dulic V, Kaufmann WK, Wilson SJ, Tlsry TD, Lees E, Harper JW, Elledge SJ, Reed SI: p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblats during radiation-induced G1 arrest. Cell 76:1013-1023, 1995.
59. Parker SB, Eichele G, Zhang P, Rawls A, Sands AT, Bradley A, Olson EN, Harper JW, Elledge SJ: p53-independent expression of p21/Cip1 in muscle and other terminally differentiation cells. Science 267:1024-1027, 1995.
60. Kamb A, Gruis NA, Weaver-Feldhaus J, Liu Q, Harshman K, Tautigian SV, Stochert E, Day RS, Johnson BE, Skolnick MH: A cell cycle regulator potentially involved in genesis of many tumor types Science 264:436-440, 1994.
61. Washimi O, Nagatalce M, Osada H, Ueda R, Koshikawa T, Seki T, Takahashi T: In vivo occurrence of p16 (MTS1) and p15 (MTS2) alterations preferentially in non-small cell lung cancers. Cancer Res 55:514-517, 1995.